The funds will strengthen research lines focused on nervous system tumors.

The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

On World Cancer Research Day, we highlight research aimed at improving treatments for both pediatric and adult cancers through innovative techniques.

The study, which provides guidelines for the clinical management of these patients, reveals that only children with a recent stem cell transplant or with other additional diseases have a higher risk of complications from COVID-19.

"Generation of a bank of surgical orthotopic PDX (patient-derived xenografts) models within the framework of a personalized medicine program in pediatric cancer" was the awarded work, of the Childhood Cancer and Hematological Diseases Group of VHIR.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

A study, co-led by Vall d’Hebron, has analysed the evolution of clinical trials with children and adolescents with cancer over the last 15 years, with the aim of optimising efficacy and defining lines for further progress.

The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.

Vall d'Hebron presents positive results from two studies in transfusion-dependent thalassaemia and severe bone marrow aplasia at the EBMT Annual Meeting on haematopoietic stem cell transplantation.

La iniciativa "Sin Piedad" explica la història d'en David, un nen que s'està tractant d'un càncer pediàtric, un exemple d'actitud lluitadora davant la malaltia.

The money will allow research into paediatric nervous system tumours and childhood sarcomas to continue, with the aim of improving children's chances of survival and reducing the side effects of treatment.

The association makes the fifth annual donation of 52,390€ that will finance a project to study new therapies for this childhood tumor.

The BEACON clinical trial, in which Vall d'Hebron participates, has observed that adding Bevacizumab to treatment with different chemotherapy drugs reduces tumor size in a greater number of patients.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

The meeting has been the meeting point of the EpSSG group dedicated to research to improve the treatment of childhood and adolescent soft tissue sarcomas.

The funds will enable the recruitment and retention of young talent, as well as the development of a new epigenetic drug

The initiative, coordinated by Dr. Pablo Velasco and Dr. Jose Luis Fuster, aims to bring innovation closer to patients and promote research projects in this disease.

On World Cancer Research Day, we highlight the oncology research model of the Vall d'Hebron Campus that allows laboratory results to be transferred as quickly as possible to clinical practice.

This initiative has several collaborative projects with the aim of increasing knowledge about rare blood diseases and improving patient care.

The multicenter phase 1 trial has been conducted in patients aged 2 to 21 years with solid tumors unresponsive to standard treatments or in relapse.

Recently, a closing meeting was organised to wrap up the first phase of the study, which aims at grouping sufficient data of patient affected by these pathologies.

The presentations include the one given by Dr. María Pérez Torres, who received the award for the best oral communication for a project on the use of mesenchymal cells to reduce complications after hematopoietic progenitor transplantation.

Thanks to the donation, the Childhood Cancer and Blood Disorders group at VHIR is doing research to explore the use of liquid biopsy for the prediction of the evolution of patients with this rare disease.

Dr. Lucas Moreno is the first author of the international work that presents a series of considerations for early phase studies with the aim of accelerating the arrival of new therapies to patients with childhood cancer.